NO20052902L - Fremgangsmate for a male opplosningshastighet til en analytt i en ikke-vandig vaeskesammensetning. - Google Patents

Fremgangsmate for a male opplosningshastighet til en analytt i en ikke-vandig vaeskesammensetning.

Info

Publication number
NO20052902L
NO20052902L NO20052902A NO20052902A NO20052902L NO 20052902 L NO20052902 L NO 20052902L NO 20052902 A NO20052902 A NO 20052902A NO 20052902 A NO20052902 A NO 20052902A NO 20052902 L NO20052902 L NO 20052902L
Authority
NO
Norway
Prior art keywords
analyte
dissolution rate
liquid composition
aqueous liquid
aqueous
Prior art date
Application number
NO20052902A
Other languages
English (en)
Inventor
Edward L Ciolkowski
Leslie C Eaton
Randal Lee Schaupaugh
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of NO20052902L publication Critical patent/NO20052902L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N13/00—Investigating surface or boundary effects, e.g. wetting power; Investigating diffusion effects; Analysing materials by determining surface, boundary, or diffusion effects
    • G01N2013/006—Dissolution of tablets or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

En fremgangsmåte blir tilveiebragt for å bestemme oppløsningshastigheten til en analytt, som helst er en farmasøytisk aktiv komponent i en langvarig fiigjøringsdoseringsform. Fremgangsmåten omfatter (i) å la en fortyrmet ikke-vandig sammensetning som irmeholder analytten og en ikke-vandig base slik som en voks eller en fett, komme i kontakt med et vandig oppløsningsmedium i en på forhånd bestemt tid, og (U) å måle mengden analytt i det vandige oppløsningsmediet.
NO20052902A 2002-11-27 2005-06-14 Fremgangsmate for a male opplosningshastighet til en analytt i en ikke-vandig vaeskesammensetning. NO20052902L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42926002P 2002-11-27 2002-11-27
PCT/US2003/025854 WO2004051263A1 (en) 2002-11-27 2003-09-10 Methods of measuring the dissolution rate of an analyte in a non-aqueous liquid composition

Publications (1)

Publication Number Publication Date
NO20052902L true NO20052902L (no) 2005-06-14

Family

ID=32469308

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052902A NO20052902L (no) 2002-11-27 2005-06-14 Fremgangsmate for a male opplosningshastighet til en analytt i en ikke-vandig vaeskesammensetning.

Country Status (11)

Country Link
US (1) US20040115837A1 (no)
EP (1) EP1570262A1 (no)
JP (1) JP2006508361A (no)
KR (1) KR100679197B1 (no)
CN (1) CN1703619A (no)
AU (1) AU2003272220A1 (no)
CA (1) CA2507244A1 (no)
HR (1) HRP20050460A2 (no)
NO (1) NO20052902L (no)
RU (1) RU2300766C2 (no)
WO (1) WO2004051263A1 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006032957A1 (en) * 2004-05-26 2006-03-30 Pfizer Products Inc. In vitro predictive method
CN101361000B (zh) 2005-12-23 2013-04-17 爱尔开-阿贝优公司 用于药用产品溶出试验的方法
CA2685450A1 (en) * 2007-05-29 2009-03-12 Pharma Diagnostics Nv Reagents and methods for the determination of pk/adme-tox characteristics of new chemical entities and of drug candidates
KR101085729B1 (ko) 2009-03-12 2011-11-21 동국제약 주식회사 서방출성 미립자의 가속용출 시험방법
CN104198549A (zh) * 2014-08-29 2014-12-10 四川制药制剂有限公司 注射用头孢哌酮钠他唑巴坦钠的头孢哌酮钠含量测定方法
MX384433B (es) * 2014-10-01 2025-03-14 Boehringer Ingelheim Animal Health Usa Inc Prueba de disolución de ingredientes activos farmacéuticos hidrofóbicos tal como avermectinas con o sin pirantel.
CN105628562A (zh) * 2016-01-04 2016-06-01 华北电力科学研究院有限责任公司 一种水箱防腐材料溶出特性检测试验方法
CN109187787B (zh) * 2018-09-19 2020-01-10 昆明华润圣火药业有限公司 一种软胶囊的溶出度检测方法
GB201904757D0 (en) * 2019-04-04 2019-05-22 Biorelevant Com Ltd Biorelevant composition
US20220373446A1 (en) * 2019-06-28 2022-11-24 Janssen Pharmaceutica Nv Biorelevant dissolution media
CN110954613A (zh) * 2019-12-06 2020-04-03 浙江仙琚医药科技有限公司 一种改进后的软胶囊制剂的溶出度的测定方法
CN112305153B (zh) * 2020-10-16 2022-09-23 中石化石油工程技术服务有限公司 一种膨润土含量的自动分析检测仪及其检测方法
CN112526019B (zh) * 2020-11-24 2021-09-28 四川逢春制药有限公司 一种用hplc法检测氨美愈素口服溶液中多种成分含量的方法
CN113514370B (zh) * 2021-04-14 2024-09-27 广州呼吸药物工程技术有限公司 一种用于测定载药非血管支架药物的单向渗透性装置及测定方法
CN115248141A (zh) * 2021-04-28 2022-10-28 北京泰德制药股份有限公司 一种制备缓释药物组合物检测样品的方法
CN114858986A (zh) * 2022-07-11 2022-08-05 湖南慧泽生物医药科技有限公司 一种米拉贝隆缓释片的体外溶出方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3791222A (en) * 1972-04-07 1974-02-12 Warner Lambert Co Dissolution testing device
US3791221A (en) * 1972-04-07 1974-02-12 Warner Lambert Co Dissolution testing device
US3802272A (en) * 1973-01-24 1974-04-09 Dow Chemical Co Automatic dissolution rate determinator
US4335438A (en) * 1980-04-17 1982-06-15 Smolen Victor F Method and apparatus for automatic dissolution testing of products
CH680472A5 (no) * 1989-12-18 1992-08-31 Sotax Ag
KR100296810B1 (ko) * 1993-03-12 2001-10-24 로렌스 티. 마이젠헬더 결정성세프티오퍼유리산
US5412979A (en) * 1993-05-03 1995-05-09 Temple University - Of The Commonwealth System Of Higher Education Method and apparatus for dissolution testing of a dosage form
US6060024A (en) * 1993-07-14 2000-05-09 Zymark Corporation Automatic dissolution testing system
DE4413350A1 (de) * 1994-04-18 1995-10-19 Basf Ag Retard-Matrixpellets und Verfahren zu ihrer Herstellung
DE29519713U1 (de) * 1995-12-12 1996-02-01 Erweka GmbH, 63150 Heusenstamm Dissolutionstestgerät
WO1998020340A1 (en) * 1996-11-07 1998-05-14 Ortho Pharmaceutical Corporation A dissolution test method for solid steroidal pharmaceutical formulations
CA2358575A1 (en) * 2001-09-26 2003-03-26 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Health Low speed precision stirring/mixing device

Also Published As

Publication number Publication date
RU2300766C2 (ru) 2007-06-10
KR100679197B1 (ko) 2007-02-06
EP1570262A1 (en) 2005-09-07
KR20050085195A (ko) 2005-08-29
WO2004051263A1 (en) 2004-06-17
CA2507244A1 (en) 2004-06-17
RU2005116026A (ru) 2006-01-20
JP2006508361A (ja) 2006-03-09
CN1703619A (zh) 2005-11-30
AU2003272220A1 (en) 2004-06-23
US20040115837A1 (en) 2004-06-17
HRP20050460A2 (en) 2005-12-31

Similar Documents

Publication Publication Date Title
NO20052902L (no) Fremgangsmate for a male opplosningshastighet til en analytt i en ikke-vandig vaeskesammensetning.
Mathews et al. Gene dose-dependent alterations in extraneuronal serotonin but not dopamine in mice with reduced serotonin transporter expression
Häussinger et al. Involvement of p38MAPK in the regulation of proteolysis by liver cell hydration
Taubert et al. Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action
Paine et al. Two major grapefruit juice components differ in time to onset of intestinal CYP3A4 inhibition
HUP0102250A2 (hu) Nemstabilis dipeptidilpeptidáz IV-gátlók vegyületei, azokat tartalmazó gyógyászati készítmények és alkalmazásuk
BR9913626A (pt) Formulações de ranolazina de liberação contìnua
Raspé et al. Tonic modulation of dog thyrocyte H2O2 generation and I-uptake by thyrotropin through the cyclic adenosine 3', 5'-monophosphate cascade
NO20004721L (no) Bruseformuleringer
NO20002121L (no) Benzotiazol-protein-tyrosin-kinaseinhibitorer
DE69626117D1 (de) Orale pharmazeutische zusammensetzungen mit verzögerter freisetzung von reversiblen protonpumpen-inhibitoren
SE9600071D0 (sv) New oral formulation of two active ingredients I
AR063149A1 (es) Formulaciones a base de polipeptidos estables
Mochel et al. Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation
CY1111905T1 (el) Φαρμακευτικη συνθεση περιλαμβανουσα εναν επιλεκτικο αναστολεα της αμινοπεπτιδασης α, ειδικα τον ec33, για τη μειωση της αρτηριακης πιεσεως
HRP20020404B1 (hr) Otopine koje sadrže epinastin
EA200400808A1 (ru) СПОСОБ ИНДУЦИРОВАНИЯ ОВУЛЯЦИИ С ИСПОЛЬЗОВАНИЕМ НЕПОЛИПЕПТИДНОГО МОДУЛЯТОРА УРОВНЕЙ цАМФ
AR045061A1 (es) Formulacion farmaceutica y metodo para tratar trastornos gastrointestinales causados por acido
EE05054B1 (et) 5-HT4 agonisti v?i antagonisti peroraalne ravimkoostis ja selle kasutamine meditsiinis
Smith-Ryan et al. The influence of β-alanine supplementation on markers of exercise-induced oxidative stress
EP1552838A4 (en) RUBROFUSARIN GLYCOSIDE-CONTAINING COMPOSITION
YAMADA et al. Glutamate is not a major conveyer of ATP-sensitive K+ channel-independent glucose action in pancreatic islet β cell
DK1409449T3 (da) Alpha-ketoglutarater af aktive ingredienser og sammensætninger omfattende disse
Kari et al. Urea synthesis from ammonia in periportal and pericentral regions of the liver lobule: effect of oxygen
Tabakoff et al. Methionine lowers circulating levels of acetaldehyde after ethanol ingestion

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application